comparative efficacy of cabozantinib and regorafenib for advanced hepatocellular carcinoma
Published 4 years ago • 822 plays • Length 3:56Download video MP4
Download video MP3
Similar videos
-
7:08
final analysis of the atlantis cabozantinib comparison
-
0:46
second-linetreatment for hcc
-
1:17
inhibiting dkk1 enhances sorafenib efficacy in hcc
-
8:23
comparative data in available tkis for hcc
-
1:40
phase iii meteor trial: cabozantinib vs everolimus for advanced clear cell renal cell carcinoma
-
10:40
comparative effectiveness research and cancer
-
12:47
debate 11: locally-advanced hepatocellular carcinoma (hcc) - surgery is optimal
-
2:33
celestial trial: second-line cabozantinib’s value in hcc
-
5:42
meteor trial: cabozantinib vs everolimus in advanced renal cell carcinoma
-
11:18
debate: is there a standard second line therapy for hcc? - regorafenib is a winner
-
1:26
principles for the conduct of comparative effectiveness research
-
17:33
cycore: cyberinfrastructure for cancer comparative effectiveness research- emila farcas, phd
-
1:05
what is comparative effectiveness research (cer)?
-
3:04
researchers: more apples-to-apples comparisons needed
-
1:03:06
changing epidemiology of hepatocellular carcinoma
-
8:07
tki/io comparison: lenvatinib/pembrolizumab vs cabozantinib/nivolumab vs axitinib/pembrolizumab
-
5:08
cabosun trial of upfront cabozantinib in metastatic rcc
-
53:29
comparative effectiveness research seminar 02-23-2012
-
1:38
dr. finn on significance of phase iii findings of lenvatinib in hcc